Table of Content

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Introduction to mRNA Vaccines and Therapeutics
5.1 History of mRNA Vaccines and Therapeutics Development
5.2 Incidence and Prevalence of Chronic Diseases and Major Infectious Diseases
5.3 Prevention and Treatment Using mRNA Vaccines and Therapeutics
5.3.1 mRNA Modifications
5.3.2 mRNA Efficiencies
5.3.3 Adjuvant/Stimulant and Carrier Technologies for mRNA-Based Vaccines
5.3.4 Carriers for mRNA-Based Protein and Antibody Therapeutics

6 Global mRNA Vaccines and Therapeutics Market
6.1 Market Potential Overview
6.2 Market Potential
6.3 Impact of COVID-19
6.4 mRNA Vaccines in Pipeline

7 Market Breakup by Vaccine Type
7.1 Self-amplifying mRNA-Based Vaccines
7.2 Conventional Non-Amplifying mRNA-Based Vaccines

8 Market Breakup by Treatment Type
8.1 Gene Therapy
8.2 Monoclonal Antibody
8.3 Gene Transcription
8.4 Cell Therapy
8.5 Bioengineered Vaccine
8.6 Others

9 Market Breakup by Vaccine Manufacturing
9.1 In-House
9.2 Out-Sourced

10 Market Breakup by Application
10.1 Cancer
10.2 Infectious Disease
10.3 Gene Editing
10.4 Protein Replacement

11 Market Breakup by End-User
11.1 Hospitals and Clinics
11.2 Research Organizations
11.3 Others

12 Market Breakup by Region
12.1 North America
12.1.1 Market Breakup by Country
12.1.1.1 United States
12.1.1.2 Canada
12.2 Europe
12.2.1 Market Breakup by Country
12.2.1.1 Germany
12.2.1.2 United Kingdom
12.2.1.3 France
12.2.1.4 Italy
12.2.1.5 Spain
12.2.1.6 Russia
12.2.1.7 Others
12.3 Asia Pacific
12.3.1 Market Breakup by Country
12.3.1.1 Japan
12.3.1.2 China
12.3.1.3 Australia
12.3.1.4 South Korea
12.3.1.5 India
12.3.1.6 Indonesia
12.3.1.7 Others
12.4 Latin America
12.4.1 Market Breakup by Country
12.4.1.1 Brazil
12.4.1.2 Mexico
12.4.1.3 Others
12.5 Middle East and Africa
12.5.1 Market Breakup by Country

13 SWOT Analysis
13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis
15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes

16 Competitive Landscape
16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
16.3.1 Arcturus Therapeutics, Inc.
16.3.2 BioNTech SE
16.3.3 CureVac AG
16.3.4 eTheRNA immunotherapies NV
16.3.5 ethris GmbH
16.3.6 GlaxoSmithKline PLC
16.3.7 Moderna Therapeutics Inc.
16.3.8 Translate Bio Inc.
16.3.9 Argos Therapeutics, Inc.
16.3.10 Sangamo Therapeutics Inc.
16.3.11 Pfizer Inc.